Skip to main content

Advanced T-cell Engineered for Cancer Therapy

Objective

"T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to allow the full potential of CAR therapy to be unleashed.
At present, CAR therapy requires a bespoke autologous therapeutic product for each patient. This greatly limits practicality, scalability and commercialisation. The development of a strategy for creation of universal engineered T-cells is the first key aim of this consortium. There is an increased appreciation of the immunological hostilities (CAR) T-cells face in the tumour microenvironment, and prevention of this local immune suppressive effect will likely be critical in permitting effective tumour control. The second main aim of this proposal is therefore to engineer CAR T-cells to be resistant to the hostile microenvironment. CAR T-cells can only be effective if they can access the tumour site. Exploiting the fact that neo-angiogenesis is a hallmark of neoplastic progression, the third aim of the consortium is to utilise endothelial cues of neo-angiogenesis to direct CAR T-cell migration and activity.
The central technological theme of this consortium is the application of TALEN-mediated gene editing strategies alongside genetic modification with integrating vectors. Using this approach, we will implement a clinical study of “universal” CAR T-cells in refractory lymphoma. Further, this work will be complemented with highly focused development of T-cells which are resistant to hostile microenvironments and which can home to sites of neovascularization. The legacy this consortium wishes is commercialization of universal CAR therapy for a broad swathe of human cancers."

Field of science

  • /social sciences/sociology/social problems/migration
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

University College London
Address
Gower Street
WC1E 6BT London
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 646 887
Administrative Contact
Martin Scott (Mr.)

Participants (5)

CELLECTICS THERAPEUTICS SAS

Participation ended

France
Address
Rue De La Croix De Jarry 8
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Julianne Smith (Dr.)
CELLECTIS SA
France
EU contribution
€ 1 448 140
Address
Rue Jean Antoine De Baif 12
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Julianne Smith (Dr.)
PHILOGEN SPA
Italy
EU contribution
€ 625 900
Address
Piazza La Lizza 7
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Laura Baldi (Dr.)
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
EU contribution
€ 640 980
Address
Plesmanlaan 121
1066 CX Amsterdam
Activity type
Research Organisations
Administrative Contact
Henri Van Luenen (Dr.)
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 569 244
Address
Ramistrasse 71
8006 Zürich
Activity type
Other
Administrative Contact
Burkhard Becher (Dr.)